Pharmacist's time spent: Space for Pharmacy-based Interventions and Consultation TimE (SPICE)-an observational time and motion study.

change management health services administration & management organisation of health services primary care quality in health care

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
02 03 2022
Historique:
entrez: 3 3 2022
pubmed: 4 3 2022
medline: 28 4 2022
Statut: epublish

Résumé

To describe the pharmacists' workflow, including tasks and time spent, to better understand their work capacity. Cross-sectional, observational, time and motion study. Community pharmacies in Western Australia and New South Wales, Australia. Currently registered and practising pharmacists were approached using snowball sampling and selected using purposive techniques to obtain balance representation of metropolitan and rural pharmacies, as well as high and low script volumes where possible. Twenty-four pharmacists across 15 pharmacies participated during the 135 sessions totalling over 274 hours of observation. Dispensing (30%), indirect patient services (17%), counselling (15%) and professional management activities (15%) were the top four duties pharmacists performed, while only 2% of time was spent on professional services such as pain clinics and influenza vaccinations. Tasks were frequently interrupted and often performed simultaneously. Breaks and consumer-contact times were limited. More time was spent on professional service activities in non-metropolitan pharmacies, in pharmacies with greater daily prescription volumes and those with one or more support pharmacists. This is the first study to quantify the pharmacists' tasks in Australian community pharmacies. Much time is being spent on dispensing, supply and management activities with little time for providing additional professional services. An extra supporting pharmacist is likely necessary to increase professional services. These findings could support future research around barriers and enablers of conducive workflows and of extended professional services.

Identifiants

pubmed: 35236731
pii: bmjopen-2021-055597
doi: 10.1136/bmjopen-2021-055597
pmc: PMC8896034
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e055597

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Australas Med J. 2011;4(4):190-200
pubmed: 23393510
Pharm Pract (Granada). 2016 Oct-Dec;14(4):836
pubmed: 28042356
Med Educ. 2017 Jan;51(1):31-39
pubmed: 27580703
Can Pharm J (Ott). 2016 Jan;149(1):18-27
pubmed: 26798374
Pharm World Sci. 2010 Oct;32(5):622-30
pubmed: 20582472
Health Policy. 2015 May;119(5):628-39
pubmed: 25747809
PLoS One. 2016 Apr 04;11(4):e0152903
pubmed: 27043716
Res Social Adm Pharm. 2020 Sep;16(9):1314-1317
pubmed: 30890316
Health Expect. 2016 Oct;19(5):1098-110
pubmed: 26332335
Int J Clin Pharm. 2013 Jun;35(3):469-75
pubmed: 23549776
Res Social Adm Pharm. 2021 Dec;17(12):2136-2144
pubmed: 34312101
J Multidiscip Healthc. 2020 Mar 02;13:227-234
pubmed: 32184612
Lancet. 2003 Feb 22;361(9358):680
pubmed: 12606184
Res Social Adm Pharm. 2016 Mar-Apr;12(2):347-54
pubmed: 26072001
Int J Pharm Pract. 2020 Feb;28(1):3-12
pubmed: 31368606
Int J Pharm Pract. 2012 Aug;20(4):259-71
pubmed: 22775522
BMC Health Serv Res. 2016 Sep 29;16(1):529
pubmed: 27687973
Res Social Adm Pharm. 2017 Jan - Feb;13(1):133-147
pubmed: 26997136
BMC Health Serv Res. 2021 Sep 3;21(1):906
pubmed: 34479542
J Eval Clin Pract. 2011 Feb;17(1):97-103
pubmed: 20825538
Health Serv Res. 1993 Dec;28(5):577-97
pubmed: 8270422
J Am Med Inform Assoc. 2013 Nov-Dec;20(6):1150-8
pubmed: 23715803
Int J Pharm Pract. 2020 Oct;28(5):441-448
pubmed: 32347607
Int J Pharm Pract. 2014 Oct;22(5):309-18
pubmed: 24423212
BMC Fam Pract. 2018 May 9;19(1):54
pubmed: 29743018
Stud Health Technol Inform. 2016;227:80-6
pubmed: 27440293
Pharm Pract (Granada). 2020 Apr-Jun;18(2):1967
pubmed: 32477437
Ann Pharmacother. 2008 Jun;42(6):861-8
pubmed: 18477730
Aust Health Rev. 2019 Oct;43(5):502-507
pubmed: 31505158
Int J Med Inform. 2009 Apr;78 Suppl 1:S25-33
pubmed: 18951838
Res Social Adm Pharm. 2018 Dec;14(12):1157-1162
pubmed: 29317188

Auteurs

Ajay Karia (A)

School of Population Health, Curtin University, Perth, Western Australia, Australia ajay.karia@curtin.edu.au.

Richard Norman (R)

School of Population Health, Curtin University, Perth, Western Australia, Australia.
Faculty of Health Sciences, Curtin enAble Institute, Curtin University, Perth, Western Australia, Australia.

Suzanne Robinson (S)

School of Population Health, Curtin University, Perth, Western Australia, Australia.
Faculty of Health Sciences, Curtin enAble Institute, Curtin University, Perth, Western Australia, Australia.

Elin Lehnbom (E)

Department of Pharmacy, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, Tromsø, Norway.
Department of Health and Caring Sciences, Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden.

Tracey-Lea Laba (TL)

Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia.

Iva Durakovic (I)

Interior Architecture, Faculty of Built Environment, UNSW, Sydney, New South Wales, Australia.

Christine Balane (C)

The George Institute for Global Health, Newtown, New South Wales, Australia.

Rohina Joshi (R)

The George Institute for Global Health, Newtown, New South Wales, Australia.
The George Institute for Global Health India, New Delhi, India.

Ruth Webster (R)

Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia.
The George Institute for Global Health, Newtown, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH